Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P16070

UPID:
CD44_HUMAN

ALTERNATIVE NAMES:
CDw44; Epican; Extracellular matrix receptor III; GP90 lymphocyte homing/adhesion receptor; HUTCH-I; Heparan sulfate proteoglycan; Hermes antigen; Hyaluronate receptor; Phagocytic glycoprotein 1; Phagocytic glycoprotein I

ALTERNATIVE UPACC:
P16070; A5YRN9; B6EAT9; D3DR12; D3DR13; O95370; P22511; Q04858; Q13419; Q13957; Q13958; Q13959; Q13960; Q13961; Q13967; Q13968; Q13980; Q15861; Q16064; Q16065; Q16066; Q16208; Q16522; Q86T72; Q86Z27; Q8N694; Q92493; Q96J24; Q9H5A5; Q9UC28; Q9UC29; Q9UC30; Q9UCB0; Q9UJ36

BACKGROUND:
The CD44 antigen, also referred to as Hermes antigen and GP90 lymphocyte homing/adhesion receptor, plays a pivotal role in the activation and homing of T-lymphocytes, inflammation, and response to bacterial infection. It acts as a signaling platform by assembling protein complexes that coordinate pathways essential for cell migration and adhesion.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of CD44 antigen offers a promising avenue for therapeutic intervention. Its critical role in immune response and cell adhesion mechanisms positions it as a valuable target in developing treatments for related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.